"...Redchip presentation was impressive. Silverman knows his stuff. He first went over. Q-inside for implants, vascular ports, and sizers. He mentioned database management as a potential source of revenue. If they play it right IMO, VTEQ could be THE database manager for anybody else who uses IDs, even without Q implants.
In Q&A Silverman mentioned $40 million revenue potential, possibly linking up with Mentor and Allergan on breast implants.
BUT, to me the most opportunity is in the radiation dosimeter. Implanted in a tumor- breast or prostate (huge market) it can mark tumor location and measure actual dose of radiation at site. Could potentially give more precise measurements to reduce under/over dosage issues. Hot news (sarcasm)- underdose leads to insufficient treatment, and possible future metastases or enlargement of the original tumor. Overdose may reduce or eliminate a tumor but with enormous cost to patient health.
He also mentioned the increase in volume due to funding requirements, almost in a "I know it stinks, but lets just get it done and smoother sailing ahead"tone. It's nice that he recognized it vs. the "everything is peachy" approach.
investorshub.advfn.com/boards/...msg.aspx?message_id=104399292
(Ne Menge Zeugs zum Lesen, die springen da grad im Karree wegn VTEQ)